Cumberland Pharmaceuticals Inc.

04/24/2026 | Press release | Distributed by Public on 04/24/2026 15:08

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On April 21, 2026, the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the "Company") was held in Nashville, Tennessee. The following matters were voted upon and approved by the Company's shareholders:
(1) the election of three (2) Class I Directors;
(2) the ratification of the appointment of Carr, Riggs & Ingram, LLC as our independent registered public accounting firm for the year ending December 31, 2026;
(3) to provide shareholders an opportunity to participate in an advisory vote on executive compensation; and
(4) to provide shareholders an opportunity to participate in an advisory vote regarding the frequency of the advisory vote on the compensation of the Company's named executives.
The voting results were as follows:
For Against Withheld Abstentions % of Votes in Favor
Kenneth J. Krogulski 9,561,336 - 46,137 - 99.52%
Caroline R. Young 9,479,023 - 128,450 - 98.66%
Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2026 12,714,116 19,033 - 3,426 99.82%
Provide advisory approval of the compensation of the Company's named executive officers 9,350,671 206,888 - 49,914 99.82%
Every Year Every Other Year Every Three Years Abstentions
Provide advisory approval of the frequency of the advisory vote on the compensation of the Company's named executive officers. 1,733,309 7,437 7,844,848 21,879
Cumberland Pharmaceuticals Inc. published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 24, 2026 at 21:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]